Nagi Mahammmadzade

Nagi Mahammmadzade

Auto-generated profile, based on publicly available information

Nagi Mahammmadzade

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Children’s Hospital, Medical Center and Faculty of Medicine, University of Freiburg, Germany; VASCERN-VASCA European Reference Center

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AHAnnegret Holm
Annegret Holm
PBPascal Brouillard
Pascal Brouillard
NMNagi Mahammmadzade
Nagi Mahammmadzade
MMMehrnaz Mehrabipour
Mehrnaz Mehrabipour
ASAnna Shimbulu
Anna Shimbulu
JBJoyce Ellen Bischoff
Joyce Ellen Bischoff
We investigated the genetic basis of a previously unclassified congenital vascular anomaly in a patient with multifocal cutaneous vascular tumors. Through genomic analysis, we identified a novel heterozygous de novo germline variant in GA-binding protein-alpha ( GABPA ), an ETS family transcription factor. Histopathologic evaluation demonstrated capillary-venous lesions lacking glucose transporter 1 expression, distinguishing this entity from common infantile hemangioma. Notably, the tumor vasculature exhibited a prominent alpha-SMA-positive perivascular cell layer, with nuclear localized GABPA detected in endothelial and perivascular cells. The GABPA c.509T>G (p.L170R) variant is absent from large population databases, including gnomAD, DeCAF, and RGC-MCPS databases, indicating it is extremely rare. The affected leucine residue is highly conserved across species and located within the Pointed (PNT) domain, a critical region mediating GABPA protein-protein interactions. AlphaMissense predicts this substitution to be highly damaging. Structure-based analysis using an AlphaFold-predicted approach, combined with in silico mutagenesis and molecular interaction analyses, revealed that the L170R substitution introduces new electrostatic interactions while disrupting native hydrophobic contacts within the PNT domain. Functional assessment in zebrafish demonstrated that mosaic stromal expression of GABPA-L170R caused abnormal vascular architecture compared with GABPA-wild-type controls, establishing a direct link between this variant and disrupted vascular development. Collectively, the genetic rarity, evolutionary conservation, predicted structural perturbation, and disruptive effects on vascular development establish GABPA -L170R as likely disease-causing variant. These findings define a new molecular mechanism underlying congenital vascular tumor formation and expand the role for ETS-family transcriptional regulation in human vascular anomalies.

13 November 2023 in medRxiv
Verified
Preprint
Open access
PDF file
Friedrich G. KappFriedrich G. Kapp
Friedrich G. Kapp
FBFarhad Bazgir
Farhad Bazgir
NMNagi Mahammadzade
Nagi Mahammadzade
EVErik Vassella
Erik Vassella
YDYvonne Döring
Yvonne Döring
Jochen Karl RösslerJochen Karl Rössler
Jochen Karl Rössler
Arteriovenous malformations (AVM) are benign vascular anomalies prone to pain, bleeding, and progressive growth. Treatment is often difficult and relapse after therapy is common. AVM are mainly caused by somatic mosaicism with pathogenic variants of the RAS-MAPK pathway. However, a causative variant is not identified in all patients. Using ultra-deep next generation sequencing we identified novel somatic RIT1 indel variants in lesional tissue of three AVM patients. RIT1 – not previously implicated in AVM development – encodes a RAS-like protein that can modulate RAS-MAPK signaling. For biochemical characterization, we expressed RIT1 variants in HEK293T cells, which led to a strong increase in ERK1/2 phosphorylation. Endothelial-specific mosaic overexpression of the RIT1 indels in zebrafish embryos induced AVM formation, highlighting the functional importance in vascular development. Both ERK1/2 hyperactivation in vitro and AVM formation in vivo could be suppressed by pharmacological MEK inhibition. Targeted treatment with the MEK inhibitor trametinib led to a significant decrease in bleeding episodes and AVM size in one patient. Our findings expand the genetic spectrum of AVM by identifying RIT1 as a novel gene involved in AVM formation and pave the way for targeted treatment and clinical trials in patients with AVM.